<DOC>
	<DOCNO>NCT00773513</DOCNO>
	<brief_summary>This 2 arm safety study compare outcome respect composite endpoint all-cause mortality non-fatal cardiovascular event ( myocardial infarction , stroke ) CKD participant either dialysis receive renal replacement therapy treatment methoxy polyethylene glycol-epoetin beta reference ESAs . Participants randomize receive intravenous ( iv ) subcutaneous ( sc ) methoxy polyethylene glycol-epoetin beta follow dos : participant already receive ESA treatment , methoxy polyethylene glycol-epoetin beta administer start dose 0.6 microgram per kilogram every 2 week ( mcg/kg/2wks ) iv sc ; participant receive maintenance ESA treatment , iv sc methoxy polyethylene glycol-epoetin beta administer initial monthly dose 120 , 200 360 microgram ( mcg ) depend weekly dose ESA receive prior first methoxy polyethylene glycol-epoetin beta administration . Participants randomize reference ESA treatment receive iv sc ESAs accordance prescribe dose information .</brief_summary>
	<brief_title>A Study Assess All-Cause Mortality Cardiovascular Morbidity Participants With Chronic Kidney Disease ( CKD ) Dialysis Those Not Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta ( Mircera ) Reference Erythropoietin Stimulating Agents ( ESAs )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female participant symptomatic anemia associate CKD Participants renal anemia treat ESA : Anemia define hemoglobin ( Hb ) concentration le ( &lt; ) 11.0 gram per deciliter ( g/dL ) ( mean 2 screen value least one day maximum 2 week measurement ) clinical indication ESA treatment Participants renal anemia maintenance ESA therapy : If dialysis : regular longterm hemodialysis peritoneal dialysis therapy mode dialysis least 3 month screen Hb concentration 10 12 g/dL ( mean 2 screen value least one day maximum 2 week measurement ) Participants adequate iron status define : serum ferritin equal 100 microgram per liter transferrin saturation equal 20 percent Contraindications ESA treatment : uncontrolled hypertension , hypersensitivity active substance excipients , contraindication ESA therapy Conditions know cause inadequate response ESA treatment anemia symptomatic anemia associate CKD : History hemoglobinopathy Anemia due hemolysis Pure red cell aplasia High likelihood early withdrawal ( example , within 1 year ) interruption study Pregnancy breastfeed Women childbearing potential without effective contraception Administration another investigational drug within 1 month screening plan study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>